AIRNECFLU Trademark

Trademark Overview


On Monday, November 15, 2021, a trademark application was filed for AIRNECFLU with the United States Patent and Trademark Office. The USPTO has given the AIRNECFLU trademark a serial number of 97125105. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 1, 2024. This trademark is owned by SyneuRx International (Taiwan) Corp.. The AIRNECFLU trademark is filed in the Pharmaceutical Products category with the following description:

Antiviral drugs; antibiotics; antibiotics for animals; chemical reagent for medical purposes; chemical reagent for veterinary purposes; germicides for animals; germicides; biocides for medical purposes; germicide for human use; biocides for veterinary purposes; medicines for human purposes namely, for treatment of virus infection, neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, hyperactivity, anxiety, bipolar disorder, and other central nervous system disorders; medicines for human purposes namely, for improving basic behavioral functioning, suicidal ideation and behavior, sensorimotor gating, pain threshold, memory and cognitive functioning and loss weight; sedatives; nervines for pharmaceutical or medical purposes, namely, for treating attention deficit hyperactivity disorder (ADHD), schizophrenia, pain, depression, bipolar disorder, eating disorder, addiction disorder, personality disorder, psychotic dis...
airnecflu

General Information


Serial Number97125105
Word MarkAIRNECFLU
Filing DateMonday, November 15, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 4, 2023

Trademark Statements


Goods and ServicesAntiviral drugs; antibiotics; antibiotics for animals; chemical reagent for medical purposes; chemical reagent for veterinary purposes; germicides for animals; germicides; biocides for medical purposes; germicide for human use; biocides for veterinary purposes; medicines for human purposes namely, for treatment of virus infection, neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, hyperactivity, anxiety, bipolar disorder, and other central nervous system disorders; medicines for human purposes namely, for improving basic behavioral functioning, suicidal ideation and behavior, sensorimotor gating, pain threshold, memory and cognitive functioning and loss weight; sedatives; nervines for pharmaceutical or medical purposes, namely, for treating attention deficit hyperactivity disorder (ADHD), schizophrenia, pain, depression, bipolar disorder, eating disorder, addiction disorder, personality disorder, psychotic disorder, tic disorder, post-traumatic stress disorder, anxiety, social anxiety disorder, panic disorder, autism, Asperger's disorder, obsessive-compulsive disorder (OCD), learning disorder, Tourette's syndrome, mild cognitive disorder (MCI), benign forgetfulness, closed head injury, dementia, vascular dementia, Alzheimer's disorder, frontotemporal dementia, Parkinson's disorder, Huntington's disease, nocturnal enuresis, blepharospasm, non-epileptic seizure, premenstrual syndrome, and amyotrophic lateral sclerosis (ALS); gases for pharmaceutical or medical purposes, namely, for treating attention deficit hyperactivity disorder (ADHD), schizophrenia, pain, depression, bipolar disorder, eating disorder, addiction disorder, personality disorder, psychotic disorder, tic disorder, post-traumatic stress disorder, anxiety, social anxiety disorder, panic disorder, autism, Asperger's disorder, obsessive-compulsive disorder (OCD), learning disorder, Tourette's syndrome, mild cognitive disorder (MCI), benign forgetfulness, closed head injury, dementia, vascular dementia, Alzheimer's disorder, frontotemporal dementia, Parkinson's disorder, Huntington's disease, nocturnal enuresis, blepharospasm, non-epileptic seizure, premenstrual syndrome, and amyotrophic lateral sclerosis (ALS);nasal spray for treating respiratory tract infections caused by viruses or bacteria; oral spray for treating respiratory tract infections caused by viruses or bacteria

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSyneuRx International (Taiwan) Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Party NameSyneuRx International (Taiwan) Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Trademark Events


Event DateEvent Description
Monday, April 1, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 1, 2024ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 29, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 4, 2023PUBLISHED FOR OPPOSITION
Wednesday, June 14, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 1, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 2, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 2, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 2, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Saturday, February 11, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Saturday, February 11, 2023FINAL REFUSAL E-MAILED
Saturday, February 11, 2023FINAL REFUSAL WRITTEN
Thursday, December 29, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 29, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 25, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 25, 2022NON-FINAL ACTION E-MAILED
Thursday, August 25, 2022NON-FINAL ACTION WRITTEN
Thursday, August 25, 2022ASSIGNED TO EXAMINER
Friday, November 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 18, 2021NEW APPLICATION ENTERED